Prior treatments varied from one country to another owing to regional differences in recommended treatment schedules, drug registrations, etc. Also, because few patients in the TAGS trial had previously received PD-1/PD-L1 therapy, the impact of prior immunotherapy on FTD/TPI outcomes is unclear and will need to be examined in future studies. The gene discussed is CD274; the disease is frontotemporal dementia.